• Citer

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

par Baselga, José;Haddad, Tufia;Ciruelos Gil, Eva Maria;Vuylsteke, Peter;Ebbinghaus, Scot;Im, Ellie;Eaton, Lamar;Pathiraja, Kumudu;Gause, Christine;Mauro, David;Jones, Mary Beth;Morales, Serafin;Rugo, Hope;Awada, Ahmad ;Blum, Joanne J.L.;Tan, Antoinette R;Ewertz, Marianne;Cortes, Javier;Moy, Beverly;Ruddy, Kathryn K.J.
Référence Breast cancer research and treatment, 163, 3, page (535-544)
Publication Publié, 2017-06

Article révisé par les pairs

• Détails
• Contenu

Titre:	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
Auteur:	Baselga, José; Haddad, Tufia; Ciruelos Gil, Eva Maria; Vuylsteke, Peter; Ebbinghaus, Scot; Im, Ellie; Eaton, Lamar; Pathiraja, Kumudu; Gause, Christine; Mauro, David; Jones, Mary Beth; Morales, Serafin; Rugo, Hope; Awada, Ahmad; Blum, Joanne J.L.; Tan, Antoinette R; Ewertz, Marianne; Cortes, Javier; Moy, Beverly; Ruddy, Kathryn K.J.
Informations sur la publication:	Breast cancer research and treatment, 163, 3, page (535-544)
Statut de publication:	Publié, 2017-06
Sujet CREF:	Cancérologie
Mots-clés:	Breast cancer
	Dalotuzumab
	IGF1R
	mTOR
	Ridaforolimus
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6806
	info:doi/10.1007/s10549-017-4199-3
	info:scp/85015765509